The Annals
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 10, pp. 1478-1488. DOI 10.1345/aph.1C419
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schentag, J. J
Right arrow Articles by Forrest, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schentag, J. J
Right arrow Articles by Forrest, A.

INFECTIOUS DISEASES

OBJECTIF: Réviser les essais cliniques des fluoroquinolones chez l'être humain ainsi que les données de pharmacocinétique/pharmacodynamie pouvant prédire les résultats microbiologiques ainsi que la résistance bactérienne. Les données sur les fluoroquinolone sont analysées selon l'hypothèse qu'une valeur d'AUIC >125 peut être utilisée pour toutes les fluoroquinolone, chez tous les micro-organismes.

SOURCE DE DONNÉES: Les articles sont identifiés selon MEDLINE (1966 à 2002) ainsi que par des sources secondaires.

SÉLECTION DES ÉTUDES ET EXTRACTION DES DONNÉES: Tous les articles identifiés sont évalués et les informations pertinentes sont inclues dans cette étude.

SYNTHÈSE: Les fluoroquinolone ont une activité bactéricide concentration-dépendante. Des valeurs d'AUIC inférieur à 60 résultent en une activité principalement bactériostatique et tout effet bactéricide semble alors être secondaire à des facteurs de l'hôte (neutrophiles, macrophages). Des valeurs AUIC comprises entre 100 et 250 procurent une activité bactéricide lente. Une AUIC supérieur à 250 produit une activité bactéricide rapide et une éradication bactérienne en 24 heures.

CONCLUSIONS: Les recherches cliniques favorisent l'utilisation de AUIC >250 afin d'obtenir une activité bactéricide rapide, que la bactérie soit un gram positif ou négatif.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. Dooley, C. Flexner, J. Hackman, C. A. Peloquin, E. Nuermberger, R. E. Chaisson, and S. E. Dorman
Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations
Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4037 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Odenholt and O. Cars
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model
J. Antimicrob. Chemother., November 1, 2006; 58(5): 960 - 965.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Burkhardt, C. Lehmann, R. Madabushi, V. Kumar, H. Derendorf, and T. Welte
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
J. Antimicrob. Chemother., October 1, 2006; 58(4): 822 - 829.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. Pea, D. Poz, P. Viale, F. Pavan, and M. Furlanut
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective
J. Antimicrob. Chemother., August 1, 2006; 58(2): 380 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. R. Noel, K. E. Bowker, and A. P. MacGowan
Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4234 - 4239.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Dupont, D. Hocquet, K. Jeannot, P. Chavanet, and P. Plesiat
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa
J. Antimicrob. Chemother., April 1, 2005; 55(4): 518 - 522.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. G. Masterton, J. L. Kuti, P. J. Turner, and D. P. Nicolau
The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe
J. Antimicrob. Chemother., January 1, 2005; 55(1): 71 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. J. Campion, P. J. McNamara, and M. E. Evans
Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4733 - 4744.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. W Amsden, R. C Owens Jr, and J. S Bertino Jr
AUIC in Humans: A Fact-Based Discussion
Ann. Pharmacother., October 1, 2003; 37(10): 1518 - 1521.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schentag, J. J
Right arrow Articles by Forrest, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schentag, J. J
Right arrow Articles by Forrest, A.

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.